Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedPublications section updated with clarifications that publications are provided voluntarily by the study entry author and are auto-filled from PubMed; the Revision: v3.3.2 note is now shown.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding lapse notice was removed from the page; the rest of the study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedExpanded location list and a new last update date, while enrollment remains 159 and there are no changes to primary outcomes or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check64 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%

- Check71 days agoChange DetectedThe page updates the revision from v3.0.2 to v3.1.0, indicating a new version is available. If there is additional content tied to the release, it isn’t shown here.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element has been removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.